Immunometabolic Organ Crosstalk in Heart Failure with Preserved Ejection Fraction: The Role of Dietary Patterns in Obesity-Related Inflammation
Open Access
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a major healthcare problem affecting approximately 1–2% of the adult population in highly developed countries. It is a heterogeneous condition with cardiometabolic disorders such as obesity, insulin resistance, diabetes mellitus, and hypertension. Pathophysiologically, HFpEF is currently recognized as a systemic disease characterized not only by impaired left ventricular relaxation and increased ventricular stiffness but also by chronic inflammation, endothelial dysfunction, myocardial fibrosis, and multi-organ involvement. This study aims to investigate the role of metabolic organ crosstalk and nutritional modulation in different HFpEF phenotypes. This review analyzes the current literature to investigate the interactions between the heart, adipose tissue, liver, and spleen in the pathophysiology of HFpEF. Chronic low-grade inflammation and adipose tissue dysfunction play central roles in the progression of HFpEF by activating the immune system, favoring ectopic lipid accumulation, and exacerbating fibrosis. The identification of specific HFpEF phenotypes (e.g., obesity-related versus aging-related) requires the application of distinct nutritional strategies that target metabolic inflammation and organ crosstalk, which may improve both myocardial and systemic function. HFpEF is a complex systemic disorder that requires phenotype-specific therapeutic approaches. Precision nutrition based on specific biomarkers, together with comprehensive cardiovascular management, may enhance therapeutic efficacy and complement pharmacological treatment in patients with HFpEF.Keywords
Funding Information
- Narodowe Centrum Nauki (2020/39/D/NZ5/02514)
- CMKP (506-1-031-02-26)
This publication has 151 references indexed in Scilit:
- Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionEuropean Journal of Heart Failure, 2023
- Mesenchymal Stromal Cells Overexpressing Farnesoid X Receptor Exert Cardioprotective Effects Against Acute Ischemic Heart Injury by Binding Endogenous Bile AcidsAdvanced Science, 2022
- Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trialClinical Research in Cardiology, 2021
- Non-Alcoholic Fatty Liver Disease and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Practical IssuesESC Heart Failure, 2021
- Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later LifeJAMA Cardiology, 2020
- An Integrative Translational Approach to Study Heart Failure with Preserved Ejection Fraction: A Position Paper from the Working Group on Myocardial Function of the European Society of CardiologyEuropean Journal of Heart Failure, 2017
- Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection FractionJAMA, 2016
- Hypertrophic Cardiomyopathy and Dysregulation of Cardiac Energetics in A Mouse Model of Biliary FibrosisHepatology, 2010
- Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitisHepatology, 2007
- The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged MenJAMA, 2002